Estradiol pretreatment in GnRH antagonist protocol for IVF/ICSI treatment

We conducted a systematic review and meta-analysis of all published data to determine the impact of estradiol pretreatment on reproductive outcomes and ovary stimulation characteristics for fertilization (IVF)/intracytoplasmic sperm injection (ICSI) treatment with gonadotropin-releasing hormone (GnR...

Full description

Saved in:
Bibliographic Details
Published in:Open medicine (Warsaw, Poland) Poland), 2022-11, Vol.17 (1), p.1811-1820
Main Authors: Zhu, Shaomi, Lv, Zhexi, Song, Linjiang, Zhang, Qinxiu, Fan, Yiyue, Li, Junjun
Format: Article
Language:English
Subjects:
Birth rate
Chinese medicine
Embryos
estradiol
Estrogens
GnRH antagonist
In vitro fertilization
IVF/ICSI
Life sciences
Meta-analysis
Ovaries
Pregnancy
Sperm
Steroids
Systematic review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c534t-312ae9ace5611ab6676d3cf4f78d71786486c29832799c45ff091c2d55f17b443
cites cdi_FETCH-LOGICAL-c534t-312ae9ace5611ab6676d3cf4f78d71786486c29832799c45ff091c2d55f17b443
container_end_page 1820
container_issue 1
container_start_page 1811
container_title Open medicine (Warsaw, Poland)
container_volume 17
creator Zhu, Shaomi
Lv, Zhexi
Song, Linjiang
Zhang, Qinxiu
Fan, Yiyue
Li, Junjun
description We conducted a systematic review and meta-analysis of all published data to determine the impact of estradiol pretreatment on reproductive outcomes and ovary stimulation characteristics for fertilization (IVF)/intracytoplasmic sperm injection (ICSI) treatment with gonadotropin-releasing hormone (GnRH) antagonist protocol. MEDLINE, EMBASE, Cochrane Library, Web of Science, and China National Knowledge Infrastructure were searched, and any randomized controlled trials associated with estradiol pretreatment in GnRH antagonist protocol were included. Seven studies (1,236 patients) were included in the present study. The pooled data from the meta-analysis demonstrated no significant difference in ongoing pregnancy rate (odds ratio (OR): 0.92 (95% CI: 0.69–1.21; = 0.53) and live birth rate OR: 0.98 (95% CI: 0.74–1.30; = 0.90) between patients with and those without estradiol pretreatment in GnRH antagonist protocol. Duration of gonadotropin exposure, gonadotropin consumption, and the number of cumulus–oocyte complexes were not significantly different between groups. Luteal estradiol pretreatment in IVF/ICSI cycles with GnRH antagonist protocol in normal ovary responding population does not affect the reproductive outcomes. It is an encouraging option to facilitate cycle scheduling in GnRH antagonist protocol, for luteal estradiol pretreatment does not increase the duration of gonadotropin exposure or gonadotropin consumption.
doi_str_mv 10.1515/med-2022-0594
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_0066ce89d81a4e1facab7103e01d2d38</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_0066ce89d81a4e1facab7103e01d2d38</doaj_id><sourcerecordid>2738201809</sourcerecordid><originalsourceid>FETCH-LOGICAL-c534t-312ae9ace5611ab6676d3cf4f78d71786486c29832799c45ff091c2d55f17b443</originalsourceid><addsrcrecordid>eNptkdtrFDEUh4NYbKl99FUGfPFlbE7uARFk6WWgINTLa8gmmXWW2cmaZCr97826dW3Fp4ScL19yzg-hV4DfAQd-vgm-JZiQFnPNnqETQjW0nAn6_NH-GJ3lvMYYA6dSS_wCHVPBuJRanaDuIpdk_RDHZptCScGWTZhKM0zN1XR73dip2FWchlxqPZboKtjH1HTfLs-7xeeuOVx5iY56O-Zw9rCeoq-XF18W1-3Np6tu8fGmdZyy0lIgNmjrAhcAdimEFJ66nvVSeQlSCaaEI1pRIrV2jPc91uCI57wHuWSMnqJu7_XRrs02DRub7k20g_l9ENPK2FQGNwaDsRAuKO0VWBagt84uJWAaMHjiqaquD3vXdl7WWbraRrLjE-nTyjR8N6t4Z7SQmnNRBW8fBCn-mEMuZjNkF8bRTiHO2RBZA9CguK7om3_QdZzTVEdVKaoIBoV3VLunXIo5p9AfPgPY7DI39Tdml7nZZV751487ONB_Eq7A-z3w044lJB9Wab6vm7-v_1cMEkAB0F8Fn7mm</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2738201809</pqid></control><display><type>article</type><title>Estradiol pretreatment in GnRH antagonist protocol for IVF/ICSI treatment</title><source>NCBI_PubMed Central（免费）</source><source>Walter De Gruyter: Open Access Journals</source><creator>Zhu, Shaomi ; Lv, Zhexi ; Song, Linjiang ; Zhang, Qinxiu ; Fan, Yiyue ; Li, Junjun</creator><creatorcontrib>Zhu, Shaomi ; Lv, Zhexi ; Song, Linjiang ; Zhang, Qinxiu ; Fan, Yiyue ; Li, Junjun</creatorcontrib><description>We conducted a systematic review and meta-analysis of all published data to determine the impact of estradiol pretreatment on reproductive outcomes and ovary stimulation characteristics for fertilization (IVF)/intracytoplasmic sperm injection (ICSI) treatment with gonadotropin-releasing hormone (GnRH) antagonist protocol. MEDLINE, EMBASE, Cochrane Library, Web of Science, and China National Knowledge Infrastructure were searched, and any randomized controlled trials associated with estradiol pretreatment in GnRH antagonist protocol were included. Seven studies (1,236 patients) were included in the present study. The pooled data from the meta-analysis demonstrated no significant difference in ongoing pregnancy rate (odds ratio (OR): 0.92 (95% CI: 0.69–1.21; = 0.53) and live birth rate OR: 0.98 (95% CI: 0.74–1.30; = 0.90) between patients with and those without estradiol pretreatment in GnRH antagonist protocol. Duration of gonadotropin exposure, gonadotropin consumption, and the number of cumulus–oocyte complexes were not significantly different between groups. Luteal estradiol pretreatment in IVF/ICSI cycles with GnRH antagonist protocol in normal ovary responding population does not affect the reproductive outcomes. It is an encouraging option to facilitate cycle scheduling in GnRH antagonist protocol, for luteal estradiol pretreatment does not increase the duration of gonadotropin exposure or gonadotropin consumption.</description><identifier>ISSN: 2391-5463</identifier><identifier>EISSN: 2391-5463</identifier><identifier>DOI: 10.1515/med-2022-0594</identifier><identifier>PMID: 36457798</identifier><language>eng</language><publisher>Poland: De Gruyter</publisher><subject>Birth rate ; Chinese medicine ; Embryos ; estradiol ; Estrogens ; GnRH antagonist ; In vitro fertilization ; IVF/ICSI ; Life sciences ; Meta-analysis ; Ovaries ; Pregnancy ; Sperm ; Steroids ; Systematic review</subject><ispartof>Open medicine (Warsaw, Poland), 2022-11, Vol.17 (1), p.1811-1820</ispartof><rights>2022 the author(s), published by De Gruyter.</rights><rights>2022. This work is published under http://creativecommons.org/licenses/by/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 the author(s), published by De Gruyter 2022 the author(s), published by De Gruyter</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c534t-312ae9ace5611ab6676d3cf4f78d71786486c29832799c45ff091c2d55f17b443</citedby><cites>FETCH-LOGICAL-c534t-312ae9ace5611ab6676d3cf4f78d71786486c29832799c45ff091c2d55f17b443</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679556/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679556/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793,67158,68942</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36457798$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhu, Shaomi</creatorcontrib><creatorcontrib>Lv, Zhexi</creatorcontrib><creatorcontrib>Song, Linjiang</creatorcontrib><creatorcontrib>Zhang, Qinxiu</creatorcontrib><creatorcontrib>Fan, Yiyue</creatorcontrib><creatorcontrib>Li, Junjun</creatorcontrib><title>Estradiol pretreatment in GnRH antagonist protocol for IVF/ICSI treatment</title><title>Open medicine (Warsaw, Poland)</title><addtitle>Open Med (Wars)</addtitle><description>We conducted a systematic review and meta-analysis of all published data to determine the impact of estradiol pretreatment on reproductive outcomes and ovary stimulation characteristics for fertilization (IVF)/intracytoplasmic sperm injection (ICSI) treatment with gonadotropin-releasing hormone (GnRH) antagonist protocol. MEDLINE, EMBASE, Cochrane Library, Web of Science, and China National Knowledge Infrastructure were searched, and any randomized controlled trials associated with estradiol pretreatment in GnRH antagonist protocol were included. Seven studies (1,236 patients) were included in the present study. The pooled data from the meta-analysis demonstrated no significant difference in ongoing pregnancy rate (odds ratio (OR): 0.92 (95% CI: 0.69–1.21; = 0.53) and live birth rate OR: 0.98 (95% CI: 0.74–1.30; = 0.90) between patients with and those without estradiol pretreatment in GnRH antagonist protocol. Duration of gonadotropin exposure, gonadotropin consumption, and the number of cumulus–oocyte complexes were not significantly different between groups. Luteal estradiol pretreatment in IVF/ICSI cycles with GnRH antagonist protocol in normal ovary responding population does not affect the reproductive outcomes. It is an encouraging option to facilitate cycle scheduling in GnRH antagonist protocol, for luteal estradiol pretreatment does not increase the duration of gonadotropin exposure or gonadotropin consumption.</description><subject>Birth rate</subject><subject>Chinese medicine</subject><subject>Embryos</subject><subject>estradiol</subject><subject>Estrogens</subject><subject>GnRH antagonist</subject><subject>In vitro fertilization</subject><subject>IVF/ICSI</subject><subject>Life sciences</subject><subject>Meta-analysis</subject><subject>Ovaries</subject><subject>Pregnancy</subject><subject>Sperm</subject><subject>Steroids</subject><subject>Systematic review</subject><issn>2391-5463</issn><issn>2391-5463</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNptkdtrFDEUh4NYbKl99FUGfPFlbE7uARFk6WWgINTLa8gmmXWW2cmaZCr97826dW3Fp4ScL19yzg-hV4DfAQd-vgm-JZiQFnPNnqETQjW0nAn6_NH-GJ3lvMYYA6dSS_wCHVPBuJRanaDuIpdk_RDHZptCScGWTZhKM0zN1XR73dip2FWchlxqPZboKtjH1HTfLs-7xeeuOVx5iY56O-Zw9rCeoq-XF18W1-3Np6tu8fGmdZyy0lIgNmjrAhcAdimEFJ66nvVSeQlSCaaEI1pRIrV2jPc91uCI57wHuWSMnqJu7_XRrs02DRub7k20g_l9ENPK2FQGNwaDsRAuKO0VWBagt84uJWAaMHjiqaquD3vXdl7WWbraRrLjE-nTyjR8N6t4Z7SQmnNRBW8fBCn-mEMuZjNkF8bRTiHO2RBZA9CguK7om3_QdZzTVEdVKaoIBoV3VLunXIo5p9AfPgPY7DI39Tdml7nZZV751487ONB_Eq7A-z3w044lJB9Wab6vm7-v_1cMEkAB0F8Fn7mm</recordid><startdate>20221121</startdate><enddate>20221121</enddate><creator>Zhu, Shaomi</creator><creator>Lv, Zhexi</creator><creator>Song, Linjiang</creator><creator>Zhang, Qinxiu</creator><creator>Fan, Yiyue</creator><creator>Li, Junjun</creator><general>De Gruyter</general><general>Walter de Gruyter GmbH</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20221121</creationdate><title>Estradiol pretreatment in GnRH antagonist protocol for IVF/ICSI treatment</title><author>Zhu, Shaomi ; Lv, Zhexi ; Song, Linjiang ; Zhang, Qinxiu ; Fan, Yiyue ; Li, Junjun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c534t-312ae9ace5611ab6676d3cf4f78d71786486c29832799c45ff091c2d55f17b443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Birth rate</topic><topic>Chinese medicine</topic><topic>Embryos</topic><topic>estradiol</topic><topic>Estrogens</topic><topic>GnRH antagonist</topic><topic>In vitro fertilization</topic><topic>IVF/ICSI</topic><topic>Life sciences</topic><topic>Meta-analysis</topic><topic>Ovaries</topic><topic>Pregnancy</topic><topic>Sperm</topic><topic>Steroids</topic><topic>Systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhu, Shaomi</creatorcontrib><creatorcontrib>Lv, Zhexi</creatorcontrib><creatorcontrib>Song, Linjiang</creatorcontrib><creatorcontrib>Zhang, Qinxiu</creatorcontrib><creatorcontrib>Fan, Yiyue</creatorcontrib><creatorcontrib>Li, Junjun</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Open medicine (Warsaw, Poland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhu, Shaomi</au><au>Lv, Zhexi</au><au>Song, Linjiang</au><au>Zhang, Qinxiu</au><au>Fan, Yiyue</au><au>Li, Junjun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Estradiol pretreatment in GnRH antagonist protocol for IVF/ICSI treatment</atitle><jtitle>Open medicine (Warsaw, Poland)</jtitle><addtitle>Open Med (Wars)</addtitle><date>2022-11-21</date><risdate>2022</risdate><volume>17</volume><issue>1</issue><spage>1811</spage><epage>1820</epage><pages>1811-1820</pages><issn>2391-5463</issn><eissn>2391-5463</eissn><abstract>We conducted a systematic review and meta-analysis of all published data to determine the impact of estradiol pretreatment on reproductive outcomes and ovary stimulation characteristics for fertilization (IVF)/intracytoplasmic sperm injection (ICSI) treatment with gonadotropin-releasing hormone (GnRH) antagonist protocol. MEDLINE, EMBASE, Cochrane Library, Web of Science, and China National Knowledge Infrastructure were searched, and any randomized controlled trials associated with estradiol pretreatment in GnRH antagonist protocol were included. Seven studies (1,236 patients) were included in the present study. The pooled data from the meta-analysis demonstrated no significant difference in ongoing pregnancy rate (odds ratio (OR): 0.92 (95% CI: 0.69–1.21; = 0.53) and live birth rate OR: 0.98 (95% CI: 0.74–1.30; = 0.90) between patients with and those without estradiol pretreatment in GnRH antagonist protocol. Duration of gonadotropin exposure, gonadotropin consumption, and the number of cumulus–oocyte complexes were not significantly different between groups. Luteal estradiol pretreatment in IVF/ICSI cycles with GnRH antagonist protocol in normal ovary responding population does not affect the reproductive outcomes. It is an encouraging option to facilitate cycle scheduling in GnRH antagonist protocol, for luteal estradiol pretreatment does not increase the duration of gonadotropin exposure or gonadotropin consumption.</abstract><cop>Poland</cop><pub>De Gruyter</pub><pmid>36457798</pmid><doi>10.1515/med-2022-0594</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2391-5463
ispartof Open medicine (Warsaw, Poland), 2022-11, Vol.17 (1), p.1811-1820
issn 2391-5463
2391-5463
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_0066ce89d81a4e1facab7103e01d2d38
source NCBI_PubMed Central（免费）; Walter De Gruyter: Open Access Journals
subjects Birth rate
Chinese medicine
Embryos
estradiol
Estrogens
GnRH antagonist
In vitro fertilization
IVF/ICSI
Life sciences
Meta-analysis
Ovaries
Pregnancy
Sperm
Steroids
Systematic review
title Estradiol pretreatment in GnRH antagonist protocol for IVF/ICSI treatment
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T03%3A37%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Estradiol%20pretreatment%20in%20GnRH%20antagonist%20protocol%20for%20IVF/ICSI%20treatment&rft.jtitle=Open%20medicine%20(Warsaw,%20Poland)&rft.au=Zhu,%20Shaomi&rft.date=2022-11-21&rft.volume=17&rft.issue=1&rft.spage=1811&rft.epage=1820&rft.pages=1811-1820&rft.issn=2391-5463&rft.eissn=2391-5463&rft_id=info:doi/10.1515/med-2022-0594&rft_dat=%3Cproquest_doaj_%3E2738201809%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c534t-312ae9ace5611ab6676d3cf4f78d71786486c29832799c45ff091c2d55f17b443%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2738201809&rft_id=info:pmid/36457798&rfr_iscdi=true